Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2018 - 2021)

Summit Therapeutics (SMMT) has reported Non-Current Deffered Revenue for 4 consecutive years, with $365000.0 the latest figure, recorded in Q2 2021.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $365000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $365000.0 (changed N/A YoY) and the FY2020 annual result came in at $569000.0, up 15.42% from the prior year.
• Non-Current Deffered Revenue fell to $365000.0 in Q2 2021 per SMMT's latest filing, from $383000.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for SMMT reached as high as $36.8 million in Q1 2018 and fell as low as $365000.0 in Q2 2021.
• A 4-year average of $6.2 million and a median of $737894.2 in 2019 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue tumbled 97.1% — and 2020, when it advanced 18.33%.
• Year by year, Non-Current Deffered Revenue stood at $1.2 million in 2018, then slumped by 61.27% to $480861.1 in 2019, then increased by 18.33% to $569000.0 in 2020, then tumbled by 35.85% to $365000.0 in 2021.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $365000.0, $383000.0, and $569000.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.